期刊文献+

肝癌术后抗乙型肝炎病毒治疗对预防肝癌复发的研究 被引量:7

Liver cancer treatment after surgery for prevention of hepatitis B virus recurrence of liver cancer
下载PDF
导出
摘要 目的探讨肝癌手术后抗乙型肝炎病毒(HBV)治疗对预防肝癌复发的效果及影响。方法将20例并发乙型肝癌病毒复制的肝癌患者随机分为两组:对照组10例,单纯接受了肝癌根治术;治疗组10例,在肝癌根治术后应用拉米夫定进行抗病毒治疗。观察比较两组患者肝功能,HBV DNA定量,Child-pugh积分及生存率。结果治疗组较对照组肝功能改善明显(P<0 01);术后12月月个时,治疗组HBV DNA定量水平及Child-pugh评分明显小于治疗1个月时及对照组,差异有统计学意义(P<0.01)。治疗组平均生存时间为(23.4±2.2)个月,明显高于对照组(15.1±2.1)个月,差异有统计学意义(P<0.01)。结论肝癌术后给予抗HBV治疗对预防肝癌复发效果良好。 Objective To investigate the anti _ hepatitis B virus after liver surgery to prevent recurrence of liver cancer treatment effects and impact.Methods Twenty cases with hepatitis B virus replication in liver cancer liver cancer were randomly divided into two groups:control group (n = 10) for radical resection of hepatocellular carcinoma only;treatment group(n = 10) for liver cancer after radical resection of lamivudine antiviral therapy.Liver function,HBV DNA quantification, Child-pugh score and survival of the two groups were observed and compared.Results In the treatment group,the liver function improved more significantly than the control group(F0. 01);12 months later,the treatment group's quantitative HBV DNA levels and Child - pugh score were significantly lower than those in January and of the control group.There was significant difference (P0.01).The average survival time of treated group was(23.4±2.2) months,significantly higher than the control group(15.1±2.1) months.The difference was statistically significant (P0.01).Conclusion The effect of anti - hepatitis B virus after liver surgery to prevent recurrence of liver cancer is obvious.
出处 《实用临床医药杂志》 CAS 2011年第7期112-113,122,共3页 Journal of Clinical Medicine in Practice
关键词 肝癌 治疗 抗乙型肝炎病毒 复发 hepatocellular carcinoma against hepatitis b virus recurrence
  • 相关文献

参考文献8

二级参考文献56

共引文献17

同被引文献59

  • 1王捷.重视抗HBV在肝癌治疗中的作用[J].外科研究与新技术,2013,2(4):225-228. 被引量:2
  • 2郑梅珍.原发性肝癌手术前后的护理[J].国际医药卫生导报,2005,11(15):53-54. 被引量:2
  • 3Diez M, Medrano M, Mugtierza JM, et al. Influence of tumor localiza- tion on the prognostic value of P53 protein in colorectal adenocarcino- mas [J] . Anticancer Res, 2000, 20 (5C) : 3907-3912.
  • 4中国抗癌协会肝癌专业委员会.原发性肝癌的I临床诊断与分期标准[J].中国肝脏病杂志,2001,9(6):324.
  • 5Chen G, Lin W, Shen F, et cd. Past HBV viral load as predictor of mor- tality and morbidity from HCC and chronic liver disease in a prospec- tive study [J] . Am J Gastroenterol, 2006, 101 (8) : 1797-1803.
  • 6Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J] . JAMA, 2006, 295 (1) : 65-73.
  • 7Kubo S, Tanaka H, Takemura S, et aL Effects of lamivudine on out- come after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus [J] . Hepatol Res, 2007, 37 (2) : 94-100.
  • 8Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production [J] . Science, 2007, 317 (5834) : 121-124.
  • 9Li N, Lai EC, Shi J, Guo WX, etal. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-ac- tive phase of hepatitis B virus infection [J] . Ann Surg Oncol, 2010, 17 (1) : 179-185.
  • 10Kuzuya T, Katano Y, Kumada T, et all. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma [ J] . J Gastroenterol Hepatol, 2007, 22 (11) : 1929-1935.

引证文献7

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部